论文部分内容阅读
目的评价吡格列酮对女性2型糖尿病患者骨密度及部分骨代谢指标的影响。方法选取103例绝经后女性2型糖尿病患者,随机分为A、B组,B组在A组常规治疗的基础上加服吡格列酮15 mg/d,比较两组用药前后的骨密度及部分骨代谢指标变化。结果用药后,A组骨密度下降不明显(P>0.05);B组腰椎及左股骨颈骨密度均明显下降(P<0.05);且B组骨密度明显低于A组(P<0.05)。用药后B组骨钙素及降钙素均明显低于A组(P<0.05)。结论吡格列酮可能存在致绝经后女性2型糖尿病患者骨质疏松的风险。
Objective To evaluate the effects of pioglitazone on bone mineral density and some bone metabolic parameters in women with type 2 diabetes mellitus. Methods A total of 103 postmenopausal women with type 2 diabetes mellitus (T2DM) were enrolled and divided randomly into groups A and B. Group B received pioglitazone 15 mg / d on the basis of conventional treatment in group A. The bone mineral density and partial bone metabolism were compared before and after treatment Indicator changes. Results After treatment, the BMD of group A was significantly lower than that of group A (P <0.05), but the BMD of group B was significantly lower than that of group A (P <0.05) . After treatment, osteocalcin and calcitonin in group B were significantly lower than those in group A (P <0.05). Conclusion Pioglitazone may cause osteoporosis in postmenopausal women with type 2 diabetes mellitus.